 | • レポートコード：MRC2-11QY11942 • 出版社/出版日：QYResearch / 2020年11月25日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は線維筋痛症治療薬のグローバル市場について調査・分析したレポートです。種類別（セロトニンノルエピネフリン再取り込み阻害薬、GABAアナログ、その他）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別線維筋痛症治療薬の競争状況、市場シェア ・世界の線維筋痛症治療薬市場：種類別市場規模 2015年-2020年（セロトニンノルエピネフリン再取り込み阻害薬、GABAアナログ、その他） ・世界の線維筋痛症治療薬市場：種類別市場規模予測 2021年-2026年（セロトニンノルエピネフリン再取り込み阻害薬、GABAアナログ、その他） ・世界の線維筋痛症治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、その他） ・世界の線維筋痛症治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、その他） ・北米の線維筋痛症治療薬市場分析：米国、カナダ ・ヨーロッパの線維筋痛症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの線維筋痛症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の線維筋痛症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの線維筋痛症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Eli Lilly、Actavis、Merck Sharp and Dohme、Daiichi Sankyo、Innovative Med Concepts、Meda、Meiji Seika、Switch Biotech、Theravance、Zynerba Pharmaceuticals、Tonix Pharmaceuticals Holding Corp. (TNXP) ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Fibromyalgia (FM) is a medical condition characterised by chronic widespread pain and a heightened pain response to pressure.
The APAC is a major untapped market with many leading vendors in the global fibromyalgia drugs market.
Market Analysis and Insights: Global Fibromyalgia Drugs Market
The global Fibromyalgia Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Fibromyalgia Drugs Scope and Market Size
Fibromyalgia Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Fibromyalgia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Eli Lilly
Actavis
Merck Sharp and Dohme
Daiichi Sankyo
Innovative Med Concepts
Meda
Meiji Seika
Switch Biotech
Theravance
Zynerba Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. (TNXP)
Market segment by Type, the product can be split into
Serotonin Norepinephrine Reuptake Inhibitors
GABA Analogs
Other
Market segment by Application, split into
Hospitals
Clinics
Other
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Fibromyalgia Drugs Revenue
1.4 Market by Type
1.4.1 Global Fibromyalgia Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Serotonin Norepinephrine Reuptake Inhibitors
1.4.3 GABA Analogs
1.4.4 Other
1.5 Market by Application
1.5.1 Global Fibromyalgia Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Fibromyalgia Drugs Market Perspective (2015-2026)
2.2 Global Fibromyalgia Drugs Growth Trends by Regions
2.2.1 Fibromyalgia Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Fibromyalgia Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Fibromyalgia Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Fibromyalgia Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Fibromyalgia Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Fibromyalgia Drugs Players by Market Size
3.1.1 Global Top Fibromyalgia Drugs Players by Revenue (2015-2020)
3.1.2 Global Fibromyalgia Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Fibromyalgia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Fibromyalgia Drugs Market Concentration Ratio
3.2.1 Global Fibromyalgia Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Fibromyalgia Drugs Revenue in 2019
3.3 Fibromyalgia Drugs Key Players Head office and Area Served
3.4 Key Players Fibromyalgia Drugs Product Solution and Service
3.5 Date of Enter into Fibromyalgia Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Fibromyalgia Drugs Historic Market Size by Type (2015-2020)
4.2 Global Fibromyalgia Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Fibromyalgia Drugs Market Size by Application (2015-2020)
5.2 Global Fibromyalgia Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Fibromyalgia Drugs Market Size (2015-2020)
6.2 Fibromyalgia Drugs Key Players in North America (2019-2020)
6.3 North America Fibromyalgia Drugs Market Size by Type (2015-2020)
6.4 North America Fibromyalgia Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Fibromyalgia Drugs Market Size (2015-2020)
7.2 Fibromyalgia Drugs Key Players in Europe (2019-2020)
7.3 Europe Fibromyalgia Drugs Market Size by Type (2015-2020)
7.4 Europe Fibromyalgia Drugs Market Size by Application (2015-2020)
8 China
8.1 China Fibromyalgia Drugs Market Size (2015-2020)
8.2 Fibromyalgia Drugs Key Players in China (2019-2020)
8.3 China Fibromyalgia Drugs Market Size by Type (2015-2020)
8.4 China Fibromyalgia Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Fibromyalgia Drugs Market Size (2015-2020)
9.2 Fibromyalgia Drugs Key Players in Japan (2019-2020)
9.3 Japan Fibromyalgia Drugs Market Size by Type (2015-2020)
9.4 Japan Fibromyalgia Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Fibromyalgia Drugs Market Size (2015-2020)
10.2 Fibromyalgia Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Fibromyalgia Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Fibromyalgia Drugs Market Size by Application (2015-2020)
11 India
11.1 India Fibromyalgia Drugs Market Size (2015-2020)
11.2 Fibromyalgia Drugs Key Players in India (2019-2020)
11.3 India Fibromyalgia Drugs Market Size by Type (2015-2020)
11.4 India Fibromyalgia Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Fibromyalgia Drugs Market Size (2015-2020)
12.2 Fibromyalgia Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Fibromyalgia Drugs Market Size by Type (2015-2020)
12.4 Central & South America Fibromyalgia Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Fibromyalgia Drugs Introduction
13.1.4 Pfizer Revenue in Fibromyalgia Drugs Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Eli Lilly
13.2.1 Eli Lilly Company Details
13.2.2 Eli Lilly Business Overview
13.2.3 Eli Lilly Fibromyalgia Drugs Introduction
13.2.4 Eli Lilly Revenue in Fibromyalgia Drugs Business (2015-2020)
13.2.5 Eli Lilly Recent Development
13.3 Actavis
13.3.1 Actavis Company Details
13.3.2 Actavis Business Overview
13.3.3 Actavis Fibromyalgia Drugs Introduction
13.3.4 Actavis Revenue in Fibromyalgia Drugs Business (2015-2020)
13.3.5 Actavis Recent Development
13.4 Merck Sharp and Dohme
13.4.1 Merck Sharp and Dohme Company Details
13.4.2 Merck Sharp and Dohme Business Overview
13.4.3 Merck Sharp and Dohme Fibromyalgia Drugs Introduction
13.4.4 Merck Sharp and Dohme Revenue in Fibromyalgia Drugs Business (2015-2020)
13.4.5 Merck Sharp and Dohme Recent Development
13.5 Daiichi Sankyo
13.5.1 Daiichi Sankyo Company Details
13.5.2 Daiichi Sankyo Business Overview
13.5.3 Daiichi Sankyo Fibromyalgia Drugs Introduction
13.5.4 Daiichi Sankyo Revenue in Fibromyalgia Drugs Business (2015-2020)
13.5.5 Daiichi Sankyo Recent Development
13.6 Innovative Med Concepts
13.6.1 Innovative Med Concepts Company Details
13.6.2 Innovative Med Concepts Business Overview
13.6.3 Innovative Med Concepts Fibromyalgia Drugs Introduction
13.6.4 Innovative Med Concepts Revenue in Fibromyalgia Drugs Business (2015-2020)
13.6.5 Innovative Med Concepts Recent Development
13.7 Meda
13.7.1 Meda Company Details
13.7.2 Meda Business Overview
13.7.3 Meda Fibromyalgia Drugs Introduction
13.7.4 Meda Revenue in Fibromyalgia Drugs Business (2015-2020)
13.7.5 Meda Recent Development
13.8 Meiji Seika
13.8.1 Meiji Seika Company Details
13.8.2 Meiji Seika Business Overview
13.8.3 Meiji Seika Fibromyalgia Drugs Introduction
13.8.4 Meiji Seika Revenue in Fibromyalgia Drugs Business (2015-2020)
13.8.5 Meiji Seika Recent Development
13.9 Switch Biotech
13.9.1 Switch Biotech Company Details
13.9.2 Switch Biotech Business Overview
13.9.3 Switch Biotech Fibromyalgia Drugs Introduction
13.9.4 Switch Biotech Revenue in Fibromyalgia Drugs Business (2015-2020)
13.9.5 Switch Biotech Recent Development
13.10 Theravance
13.10.1 Theravance Company Details
13.10.2 Theravance Business Overview
13.10.3 Theravance Fibromyalgia Drugs Introduction
13.10.4 Theravance Revenue in Fibromyalgia Drugs Business (2015-2020)
13.10.5 Theravance Recent Development
13.11 Zynerba Pharmaceuticals
10.11.1 Zynerba Pharmaceuticals Company Details
10.11.2 Zynerba Pharmaceuticals Business Overview
10.11.3 Zynerba Pharmaceuticals Fibromyalgia Drugs Introduction
10.11.4 Zynerba Pharmaceuticals Revenue in Fibromyalgia Drugs Business (2015-2020)
10.11.5 Zynerba Pharmaceuticals Recent Development
13.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
10.12.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Company Details
10.12.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
10.12.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Drugs Introduction
10.12.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Drugs Business (2015-2020)
10.12.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Fibromyalgia Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Fibromyalgia Drugs Revenue
Table 3. Ranking of Global Top Fibromyalgia Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Fibromyalgia Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Serotonin Norepinephrine Reuptake Inhibitors
Table 6. Key Players of GABA Analogs
Table 7. Key Players of Other
Table 8. Global Fibromyalgia Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Fibromyalgia Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Fibromyalgia Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Fibromyalgia Drugs Market Share by Regions (2015-2020)
Table 12. Global Fibromyalgia Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Fibromyalgia Drugs Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Fibromyalgia Drugs Market Growth Strategy
Table 18. Main Points Interviewed from Key Fibromyalgia Drugs Players
Table 19. Global Fibromyalgia Drugs Revenue by Players (2015-2020) (Million US$)
Table 20. Global Fibromyalgia Drugs Market Share by Players (2015-2020)
Table 21. Global Top Fibromyalgia Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fibromyalgia Drugs as of 2019)
Table 22. Global Fibromyalgia Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Fibromyalgia Drugs Product Solution and Service
Table 25. Date of Enter into Fibromyalgia Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Fibromyalgia Drugs Market Size by Type (2015-2020) (Million US$)
Table 28. Global Fibromyalgia Drugs Market Size Share by Type (2015-2020)
Table 29. Global Fibromyalgia Drugs Revenue Market Share by Type (2021-2026)
Table 30. Global Fibromyalgia Drugs Market Size Share by Application (2015-2020)
Table 31. Global Fibromyalgia Drugs Market Size by Application (2015-2020) (Million US$)
Table 32. Global Fibromyalgia Drugs Market Size Share by Application (2021-2026)
Table 33. North America Key Players Fibromyalgia Drugs Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Fibromyalgia Drugs Market Share (2019-2020)
Table 35. North America Fibromyalgia Drugs Market Size by Type (2015-2020) (Million US$)
Table 36. North America Fibromyalgia Drugs Market Share by Type (2015-2020)
Table 37. North America Fibromyalgia Drugs Market Size by Application (2015-2020) (Million US$)
Table 38. North America Fibromyalgia Drugs Market Share by Application (2015-2020)
Table 39. Europe Key Players Fibromyalgia Drugs Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Fibromyalgia Drugs Market Share (2019-2020)
Table 41. Europe Fibromyalgia Drugs Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Fibromyalgia Drugs Market Share by Type (2015-2020)
Table 43. Europe Fibromyalgia Drugs Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Fibromyalgia Drugs Market Share by Application (2015-2020)
Table 45. China Key Players Fibromyalgia Drugs Revenue (2019-2020) (Million US$)
Table 46. China Key Players Fibromyalgia Drugs Market Share (2019-2020)
Table 47. China Fibromyalgia Drugs Market Size by Type (2015-2020) (Million US$)
Table 48. China Fibromyalgia Drugs Market Share by Type (2015-2020)
Table 49. China Fibromyalgia Drugs Market Size by Application (2015-2020) (Million US$)
Table 50. China Fibromyalgia Drugs Market Share by Application (2015-2020)
Table 51. Japan Key Players Fibromyalgia Drugs Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Fibromyalgia Drugs Market Share (2019-2020)
Table 53. Japan Fibromyalgia Drugs Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Fibromyalgia Drugs Market Share by Type (2015-2020)
Table 55. Japan Fibromyalgia Drugs Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Fibromyalgia Drugs Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Fibromyalgia Drugs Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Fibromyalgia Drugs Market Share (2019-2020)
Table 59. Southeast Asia Fibromyalgia Drugs Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Fibromyalgia Drugs Market Share by Type (2015-2020)
Table 61. Southeast Asia Fibromyalgia Drugs Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Fibromyalgia Drugs Market Share by Application (2015-2020)
Table 63. India Key Players Fibromyalgia Drugs Revenue (2019-2020) (Million US$)
Table 64. India Key Players Fibromyalgia Drugs Market Share (2019-2020)
Table 65. India Fibromyalgia Drugs Market Size by Type (2015-2020) (Million US$)
Table 66. India Fibromyalgia Drugs Market Share by Type (2015-2020)
Table 67. India Fibromyalgia Drugs Market Size by Application (2015-2020) (Million US$)
Table 68. India Fibromyalgia Drugs Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Fibromyalgia Drugs Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Fibromyalgia Drugs Market Share (2019-2020)
Table 71. Central & South America Fibromyalgia Drugs Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Fibromyalgia Drugs Market Share by Type (2015-2020)
Table 73. Central & South America Fibromyalgia Drugs Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Fibromyalgia Drugs Market Share by Application (2015-2020)
Table 75. Pfizer Company Details
Table 76. Pfizer Business Overview
Table 77. Pfizer Product
Table 78. Pfizer Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 79. Pfizer Recent Development
Table 80. Eli Lilly Company Details
Table 81. Eli Lilly Business Overview
Table 82. Eli Lilly Product
Table 83. Eli Lilly Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 84. Eli Lilly Recent Development
Table 85. Actavis Company Details
Table 86. Actavis Business Overview
Table 87. Actavis Product
Table 88. Actavis Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 89. Actavis Recent Development
Table 90. Merck Sharp and Dohme Company Details
Table 91. Merck Sharp and Dohme Business Overview
Table 92. Merck Sharp and Dohme Product
Table 93. Merck Sharp and Dohme Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 94. Merck Sharp and Dohme Recent Development
Table 95. Daiichi Sankyo Company Details
Table 96. Daiichi Sankyo Business Overview
Table 97. Daiichi Sankyo Product
Table 98. Daiichi Sankyo Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 99. Daiichi Sankyo Recent Development
Table 100. Innovative Med Concepts Company Details
Table 101. Innovative Med Concepts Business Overview
Table 102. Innovative Med Concepts Product
Table 103. Innovative Med Concepts Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 104. Innovative Med Concepts Recent Development
Table 105. Meda Company Details
Table 106. Meda Business Overview
Table 107. Meda Product
Table 108. Meda Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 109. Meda Recent Development
Table 110. Meiji Seika Business Overview
Table 111. Meiji Seika Product
Table 112. Meiji Seika Company Details
Table 113. Meiji Seika Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 114. Meiji Seika Recent Development
Table 115. Switch Biotech Company Details
Table 116. Switch Biotech Business Overview
Table 117. Switch Biotech Product
Table 118. Switch Biotech Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 119. Switch Biotech Recent Development
Table 120. Theravance Company Details
Table 121. Theravance Business Overview
Table 122. Theravance Product
Table 123. Theravance Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 124. Theravance Recent Development
Table 125. Zynerba Pharmaceuticals Company Details
Table 126. Zynerba Pharmaceuticals Business Overview
Table 127. Zynerba Pharmaceuticals Product
Table 128. Zynerba Pharmaceuticals Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 129. Zynerba Pharmaceuticals Recent Development
Table 130. Tonix Pharmaceuticals Holding Corp. (TNXP) Company Details
Table 131. Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
Table 132. Tonix Pharmaceuticals Holding Corp. (TNXP) Product
Table 133. Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Drugs Business (2015-2020) (Million US$)
Table 134. Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Fibromyalgia Drugs Market Share by Type: 2020 VS 2026
Figure 2. Serotonin Norepinephrine Reuptake Inhibitors Features
Figure 3. GABA Analogs Features
Figure 4. Other Features
Figure 5. Global Fibromyalgia Drugs Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Other Case Studies
Figure 9. Fibromyalgia Drugs Report Years Considered
Figure 10. Global Fibromyalgia Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Fibromyalgia Drugs Market Share by Regions: 2020 VS 2026
Figure 12. Global Fibromyalgia Drugs Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Fibromyalgia Drugs Market Share by Players in 2019
Figure 15. Global Top Fibromyalgia Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fibromyalgia Drugs as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Fibromyalgia Drugs Revenue in 2019
Figure 17. North America Fibromyalgia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Fibromyalgia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Fibromyalgia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Fibromyalgia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Fibromyalgia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Fibromyalgia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Fibromyalgia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
アスペルガー症候群治療薬の世界市場（～2026年） The Asperger syndrome is a type of developmental disorders known as Autistic Spectrum Disorder (ASD). These disorders initiate in childhood and stay with individuals until their adult life. Children with the Asperger syndrome function better than those with autism, and they have normal intelligence …- 神経因性疼痛治療薬の世界市場（～2026年） Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia). In terms of value, North America is a large market and is expected to…
- セロトニン症候群の世界市場（～2026年） Serotonin syndrome is a group of symptoms such as high body temperature, agitation, increased reflexes, tremor, sweating, dilated pupils, diarrhoea etc. due to use of serotonergic drugs. Serious complications such as seizures and extensive muscle breakdown may occur which may lead to death. US accou…
- バーター症候群治療薬の世界市場（～2026年） Bartter syndrome is a rare genetic disorder that causes specific defects in kidney function. Market Analysis and Insights: Global Bartter Syndrome Drugs Market The global Bartter Syndrome Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% d…
- テネクテプラーゼ薬の世界市場（～2026年） Tenecteplase drug is an enzyme derived through recombinant DNA technology from a human cell line. This enzyme is used to treat thrombus (blood clots) it is also called as clot-busting drug. Tenecteplase is a bioengineered variant of the activase drug. It is estimated that North America dominated the…